Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial

References

• International Diabetes Federation, et al. IDF diabetes atlas. 9th ed. Malanda B, Karuranga S, Saeedi P, et al., editors. Brussels, Belgium: International Diabetes Federation; 2019.
   Google Scholar
• Khalid JM, Raluy-Callado M, Curtis BH, et al. Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics. Int J Clin Pract. 2014;68(1):40–48.
   PubMed Web of Science ®Google Scholar
• Comino EJ, Harris MF, Islam MD, et al. Impact of diabetes on hospital admission and length of stay among a general population aged 45 year or more: a record linkage study. BMC Health Serv Res. 2015;15(1):12.
   PubMed Web of Science ®Google Scholar
• Li S, Wang J, Zhang B, et al. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019;43(3):319–341.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Diabetes in Canada: facts and figures from a public health perspective. Ottawa; 2011.
   Google Scholar
• Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253–261.
   PubMed Web of Science ®Google Scholar
• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–862.
   PubMed Web of Science ®Google Scholar
• Rosella LC, Lebenbaum M, Fitzpatrick T, et al. Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis. Diabet Med. 2016;33(3):395–403.
   PubMed Web of Science ®Google Scholar
• Bilandzic A, Rosella L. The cost of diabetes in Canada over 10 years: applying attributable health care costs to a diabetes incidence prediction model. Health Promot Chronic Dis Prev Can. 2017;37(2):49–53.
   PubMed Web of Science ®Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732.
   PubMed Web of Science ®Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events) – DEVOTE 1 Am Heart J. 2016;179:175–183.
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) [cited Nov 2020]. Available from: https://www.meddra.org/
   Google Scholar
• IQVIA. Data on file. 2019.
   Google Scholar
• Canadian Institute for Health Information. Discharge Abstract Database metadata (DAD) 2019. [Nov 2020]. Available from: https://www.cihi.ca/en/discharge-abstract-database-metadata-dad.
   Google Scholar
• Canadian Institute for Health Information. National Ambulatory Care Reporting System metadata (NACRS) 2019. [Nov 2020]. Available from: https://www.cihi.ca/en/national-ambulatory-care-reporting-system-metadata.
   Google Scholar
• Canadian Institute for Health Information. NACRS Emergency Department Visits and Length of Stay, 2016–2017 2017. [cited Nov 2020]. Available from: https://www.cihi.ca/en/nacrs-emergency-department-visits-and-length-of-stay-2016-2017
   Google Scholar
• Efron B. Bootstrap methods: another look at the jackknife. Ann Statist. 1979;7(1):1–26.
   Web of Science ®Google Scholar
• SAS Institute Inc. Tweedie distribution for generalized linear models 2019. [cited Nov 2020]. Available from: https://documentation.sas.com/?docsetId=statug&docsetTarget=statug_genmod_details28.htm&docsetVersion=15.1&locale=en.
   Google Scholar
• Gerstein HC. Diabetes: dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11(9):508–510.
   PubMed Web of Science ®Google Scholar
• Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347(3):f4533–f4533.
   PubMed Web of Science ®Google Scholar
• Yeh JS, Sung SH, Huang HM, et al. Hypoglycemia and risk of vascular events and mortality: a systematic review and meta-analysis. Acta Diabetol. 2016;53(3):377–392.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review. Cardiovasc Diabetol. 2013;12(1):135.
   PubMed Web of Science ®Google Scholar
• Deedwania P. Dangers of hypoglycemia in cardiac patients with diabetes: time to switch to safer, newer drugs. J Am Coll Cardiol. 2018;72(15):1787–1789.
   PubMed Web of Science ®Google Scholar
• Rezende PC, Everett BM, Brooks MM, et al. Hypoglycemia and elevated troponin in patients with diabetes and coronary artery disease. J Am Coll Cardiol. 2018;72(15):1778–1786.
   PubMed Web of Science ®Google Scholar
• Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26(5):1485–1489.
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37(1):217–225.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Husain M, Lingvay I, DEVOTE Study Group, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019;18(1):156.
   PubMed Web of Science ®Google Scholar
• Amod A, Buse JB, McGuire DK, DEVOTE Study Group, et al. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: an exploratory analysis (DEVOTE 12). Diab Vasc Dis Res. 2020;17(6):1479164120970933.
   Web of Science ®Google Scholar
• Wei F, Sun X, Zhao Y, et al. Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus. BMC Nephrol. 2016;17(1):67.
   PubMed Web of Science ®Google Scholar
• Low S, Lim SC, Yeoh LY, et al. Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore. J Diabetes. 2017;9(10):908–919.
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787–800.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–184.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Valentine WJ, Marso SP, et al. Long-term cost-effectiveness of insulin degludec versus insulin glargine U100 in the UK: evidence from the basal-bolus subgroup of the DEVOTE trial (DEVOTE 16). Appl Health Econ Health Policy. 2019;17(5):615–627.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Heller S, Pieber TR, et al. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: a canadian setting (DEVOTE 9). Diabetes Obes Metab. 2019;21(7):1706–1714.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Valentine WJ, Marso SP, DEVOTE Study Group, et al. DEVOTE 5: evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal-bolus regimens for type 2 diabetes in the UK. Diabetes Ther. 2018;9(3):1217–1232.
   PubMed Web of Science ®Google Scholar
• Xu X, Grossetta Nardini HK, Ruger JP. Micro-costing studies in the health and medical literature: protocol for a systematic review. Syst Rev. 2014;3:47.
   PubMedGoogle Scholar